Point-of-Care Diagnostics Platform
OPKO Diagnostics, formerly Claros Diagnostics, Inc., has developed a point-of-care system able to produce laboratory-quality results in about ten minutes. The device includes a pipeline of diagnostic tests and a portable hardware device, and it has been acclaimed for its innovation in multiple publications.
Laboratory Quality Immunoassays
Immunoassays comprise the largest family of in-vitro diagnostics, and they are primarily used to detect proteins. They include tests for infectious diseases, cancer, and immune diseases, among others.
Due to their complexity, immunoassays typically can be only performed in large laboratories with expensive equipment and trained technicians. This limits their use to hospital or outsourced contract laboratory settings and often leads to days of waiting for lab test results.
OPKO’s groundbreaking diagnostic system is equipped to perform these complex immunoassay blood tests directly at the point-of-care in only about ten minutes.
OPKO is developing a point-of-care system based on this platform, including a pipeline of diagnostic tests and a portable hardware device.
OPKO’s diagnostic system has the potential to implement:
- Multiple tests simultaneously (multiplexing)
- Many types of complex in-vitro diagnostic assays, such as immunoassays, nucleic acid tests, hematology, coagulation, and cell counting
- Creation of diagnostic / therapeutic combinations designed to improve patient access to adequate therapies
- Monitoring of the use of therapeutics in patient treatment programs
- Neurological conditions
- Female healthcare
- Metabolic disorders
- Thyroid disorders
- Heart disease
- Infectious diseases
OPKO Diagnostics Card Technology Applications
Clinic and Blood Bank
|PSA Panel:||Panel Tests:||Cardio Panel:||STD Panel:||Key Tests:|
|Total PSA||Pre-term Bleed||CTnl||HIV||TSH, T4|
|Free PSA||Fertility||BNP||Hepatitis B||Vitamin D|
Recognition for OPKO Diagnostics:
Claros product named a finalist in the Wall Street Journal’s 2011 Technology Awards:
Claros technology successfully tested in Africa: